In Hyukmin, Choi Yong Hwan, Kang Sunghyun, Han Kyung Ho
Department of Biological Sciences and Biotechnology, Hannam University Daejeon 34054, South Korea.
Critical Diseases Diagnostics Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB) Daejeon 34141, South Korea.
Am J Cancer Res. 2025 Aug 15;15(8):3460-3470. doi: 10.62347/PSJY2877. eCollection 2025.
In this study, we introduce an innovative in vivo antibody screening method to identify antibodies that can inhibit melanoma cell growth and induce apoptosis. By using a lentiviral ScFv library, we developed a platform that allows for the direct suppression of melanoma cell proliferation within a living mouse model. Through this approach, we identified the M1 antibody, which targets PKM2, a key protein involved in tumor progression. The M1 antibody was found to significantly inhibit melanoma cell growth by disrupting the function of PKM2. Although PKM2 is widely recognized as an important factor in various cancers, no commercial therapeutic agents currently target this protein. Our findings indicate that the in vivo antibody screening method is a reliable and effective approach for isolating antibodies for melanoma therapy. Moreover, the M1 antibody shows great potential as a promising candidate for developing novel treatments for human melanoma.
在本研究中，我们引入了一种创新的体内抗体筛选方法，以鉴定能够抑制黑色素瘤细胞生长并诱导凋亡的抗体。通过使用慢病毒单链抗体库，我们开发了一个平台，该平台能够在活体小鼠模型中直接抑制黑色素瘤细胞增殖。通过这种方法，我们鉴定出了靶向PKM2的M1抗体，PKM2是一种参与肿瘤进展的关键蛋白。发现M1抗体通过破坏PKM2的功能来显著抑制黑色素瘤细胞生长。尽管PKM2被广泛认为是各种癌症中的一个重要因素，但目前尚无商业治疗药物靶向该蛋白。我们的研究结果表明，体内抗体筛选方法是分离用于黑色素瘤治疗的抗体的可靠且有效的方法。此外，M1抗体作为开发人类黑色素瘤新疗法的有前景的候选药物具有巨大潜力。
